The Kardashian fans are at it again. Over the years, they’ve managed to allege several different things about the reality TV stars – some turn out to be true and others not so much – and this time, they’re convinced they’ve touched on the reason Kris Jenner gets to maintain her beautiful figure. One word: Ozempic: the Hollywood wonder drug that’s all the rage right now.
Fans Say Kris Jenner’s New Pictures Suggests She’s Using Ozempic
Kris Jenner recently took to Instagram to post a series of pictures from her vacation in Tuscany, but fans chose to see past the perfect poses and beautiful locations to notice what they claim is a new and improved bod.
Captioning the Aug. 6 post with, “Under the Tuscan sun,” she shared pics where she wore a white maxi dress and a matching short-sleeved jacket. In reaction to the post, fans claimed she’s taking the popular weight loss drug.
Jenner ignored the comments. Earlier this year, she was faced with the same claims from fans who believe that the “Keeping Up With the Kardashians” alum slimmed down due to using Ozempic after she posted a pic where she rocked a form-fitting sleeveless yellow top.
“Looks like someone else has been into the Ozempic,” one fan commented in May, with another agreeing, “Another one on the Ozempic train.”
Khloé Kardashian, ignoring the suspicious fans, praised her mother for being “the most beautiful woman in the world.”
Perhaps, Khloé publicly supported her mom because she knows the pain of someone having their hard work to lose weight being discredited in the name of Ozempic.
Just recently, fans suspected that the “Good American” founder was getting weekly injections of the drug to lose weight.
It was something she quickly refuted, writing, “Let’s not discredit my years of working out. I get up five days a week at 6 a.m. to train. Please stop with your assumptions. I guess new year still means mean people.”
Be sure to catch up on everything happening with the Kardashians right now. Come back here often for all the Kardashians spoilers, news, and updates.